Biodesix, Inc. (BDSX) vs Myriad Genetics, Inc. (MYGN)
- Biodesix, Inc. BDSX 23.66 −4.25%
- Myriad Genetics, Inc. MYGN 3.98 −8.51%
Biodesix, Inc. and Myriad Genetics, Inc. are both Diagnostics & Research companies. Myriad Genetics, Inc. is the larger, with a market value of $416.1M against $260.7M — 1.6× the size. Biodesix, Inc. grew revenue faster over the last twelve months: 34.5% against −3.16%. Myriad Genetics, Inc. has the higher net margin (−14.0% vs −27.0%) and the higher return on invested capital (−19.9% vs −49.6%). Across the 18 metrics below, Myriad Genetics, Inc. leads on 11 and Biodesix, Inc. on 7.
Valuation
Profitability
| Metric | BDSX | MYGN | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 82.50% | 68.83% | 50.89% |
| Operating margin | (20.02%) | (12.22%) | (8.57%) |
| Net margin | (26.97%) | (13.96%) | (6.37%) |
| Free cash flow margin | (19.82%) | (1.76%) | 0.00% |
| Return on equity | (540.01%) | (32.54%) | (2.92%) |
| Return on assets | (30.33%) | (17.11%) | (6.71%) |
| Return on invested capital | (49.60%) | (19.92%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack